Afamelanotide vs Setmelanotide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Afamelanotide is a synthetic 13-amino acid superagonist analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), incorporating norleucine at position 4 and D-phenylalanine at position 7. These modifications confer ~1000-fold greater potency at MC1R than native alpha-MSH and ...
Calculate Afamelanotide dose →Setmelanotide (Imcivree) is a cyclic octapeptide MC4R agonist FDA-approved in 2020 for chronic weight management in adults and children (6+) with obesity caused by POMC deficiency, PCSK1 deficiency, or leptin receptor (LEPR) deficiency - rare genetic conditions causing extreme ea...
Calculate Setmelanotide dose →| Parameter | Afamelanotide | Setmelanotide |
|---|---|---|
| Category | Melanocortin Agonist | Melanocortin Agonist |
| Research | FDA Approved (2019) | FDA Approved (2020) |
| Half-Life | ~33-40 hours (from subcutaneous implant) | ~11 hours SC |
| Typical Dose | 16 mg SC implant every 60 days | 2-3 mg SC once daily (adults); weight-based in children |
| Frequency | Every 60 days (subcutaneous implant) | Once daily SC |
| Route | SC implant (biodegradable PLGA rod, 16 mg) | SC injection once daily |
| FDA Status | FDA approved 2019 for erythropoietic protoporphyria (EPP) - first drug for EPP in the US | FDA approved 2020 for obesity from POMC, PCSK1, or LEPR deficiency; 2022 expanded for BBS and AHC |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.